• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Arcellx Inc. (Amendment)

    3/25/24 6:41:27 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACLX alert in real time by email
    SC 13D/A 1 d817285dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    Arcellx, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001

    (Title of Class of Securities)

    03940C 10 0

    (CUSIP Number)

    Sasha Keough

    c/o SR One Capital Management, LP

    985 Old Eagle School Road, Suite 511

    Wayne, PA 19087

    410-800-7503

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    March 21, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     


    CUSIP No. 03940C 10 0    Schedule 13D/A    Page 2

     

     1   

     NAME OF REPORTING PERSON

     

     SR One Capital Management, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     2,346,630(1)

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     2,346,630 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,346,630 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     4.44% (2)

    14  

     TYPE OF REPORTING PERSON

     

     OO

     

    (1)

    Consists of (i) 1,479,148 shares of Common Stock held of record by SR One Capital Fund I Aggregator, LP and (ii) 867,482 shares held of record by SR One Co-Invest II, LLC.

    (2)

    Based upon 52,796,618 shares of common stock (the “Common Stock”) of Arcellx, Inc. (the “Issuer”) reported to be outstanding as of February 23, 2024, on the Issuer’s Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2024.


    CUSIP No. 03940C 10 0    Schedule 13D/A    Page 3

     

     1   

     NAME OF REPORTING PERSON OR

     I.R.S. IDENTIFICATION NO. OF ABOVE

     

     SR One Capital Fund I Aggregator, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     1,479,148

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     1,479,148

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,479,148

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     2.8% (1)

    14  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    Based upon 52,796,618 shares of Common Stock of the Issuer reported to be outstanding as of February 23, 2024, on the Issuer’s Form 10-K filed with the SEC on February 28, 2024.


    CUSIP No. 03940C 10 0    Schedule 13D/A    Page 4

     

     1   

     NAME OF REPORTING PERSON OR

     I.R.S. IDENTIFICATION NO. OF ABOVE

     

     SR One Capital Partners I, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     1,479,148 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     1,479,148 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,479,148 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     2.8% (2)

    14  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    All shares are held of record by SR One Capital Fund I Aggregator, LP.

    (2)

    Based upon 52,796,618 shares of Common Stock of the Issuer reported to be outstanding as of February 23, 2024, on the Issuer’s Form 10-K filed with the SEC on February 28, 2024.


    CUSIP No. 03940C 10 0    Schedule 13D/A    Page 5

     

     1   

     NAME OF REPORTING PERSON OR

     I.R.S. IDENTIFICATION NO. OF ABOVE

     

     SR One Co-Invest II, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     867,482

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     867,482

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     867,482

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     1.64% (1)

    14  

     TYPE OF REPORTING PERSON

     

     OO

     

    (1)

    Based upon 52,796,618 shares of Common Stock of the Issuer reported to be outstanding as of February 23, 2024, on the Issuer’s Form 10-K filed with the SEC on February 28, 2024.


    CUSIP No. 03940C 10 0    Schedule 13D/A    Page 6

     

     1   

     NAME OF REPORTING PERSON OR

     I.R.S. IDENTIFICATION NO. OF ABOVE

     

     SR One Co-Invest II Manager, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     867,482 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     867,482 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     867,482 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     1.64% (2)

    14  

     TYPE OF REPORTING PERSON

     

     OO

     

    (1)

    All shares are held of record by SR One Co-Invest II, LLC.

    (2)

    Based upon 52,796,618 shares of Common Stock of the Issuer reported to be outstanding as of February 23, 2024, on the Issuer’s Form 10-K filed with the SEC on February 28, 2024.


    CUSIP No. 03940C 10 0    Schedule 13D/A    Page 7

     

     1   

     NAME OF REPORTING PERSON OR

     I.R.S. IDENTIFICATION NO. OF ABOVE

     

     Simeon George

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     2,346,630 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     2,346,630 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,346,630 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     4.44% (2)

    14  

     TYPE OF REPORTING PERSON

     

     IN

     

    (1)

    Consists of (i) 1,479,148 shares of Common Stock held of record by SR One Capital Fund I Aggregator, LP and (ii) 867,482 shares held of record by SR One Co-Invest II, LLC.

    (2)

    Based upon 52,796,618 shares of Common Stock of the Issuer reported to be outstanding as of February 23, 2024, on the Issuer’s Form 10-K filed with the SEC on February 28, 2024.


    CUSIP No. 03940C 10 0    Schedule 13D/A    Page 8

     

    Item 1.

    Security and Issuer.

    Item 1 of the Schedule 13D is hereby amended and supplemented as follows:

    This Amendment No. 5 (this “Amendment No. 5”) to Schedule 13D amends and supplements the statements on the Schedule 13D originally filed with the SEC by the Reporting Persons on February 17, 2022, Amendment No. 1 filed with the SEC by the Reporting Persons on June 27, 2022, Amendment No. 2 filed with the SEC by the Reporting Persons on May 19, 2023 (“Amendment No. 2”), Amendment No. 3 filed with the SEC by the Reporting Persons on June 2, 2023 (“Amendment No. 3”) and Amendment No. 4 filed with the SEC by the Reporting Persons on December 18, 2023 (“Amendment No. 4”) relating to the common stock, $0.0001 par value per share (the “Common Stock”) of Arcellx, Inc., a Delaware corporation (the “Issuer”). The address of the Issuer’s principal executive offices is 25 West Watkins Mill Road, Suite A, Gaithersburg, Maryland 20878.

    Certain terms used but not defined in this Amendment No. 5 have the meanings assigned thereto in the Schedule 13D (including Amendment No. 1, Amendment No. 2, Amendment No. 3 and Amendment No. 4 thereto). Except as specifically provided herein, this Amendment No. 5 does not modify any of the information previously reported on the Schedule 13D (including Amendment No. 1, Amendment No. 2, Amendment No. 3 and Amendment No. 4 thereto).

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

    N/A. The Reporting Persons sold Common Stock.

     

    Item 4.

    Purpose of Transaction.

    The response set forth in Item 4 of the Schedule 13D is hereby supplemented as follows:

    On March 21, 2024, (1) SR One Fund I Aggregator LP (“Aggregator”) sold 504,263 shares of the Issuer’s Common Stock and (2) SR One Co-Invest II, LLC (“Co-Invest II”) sold 295,737 shares of the Issuer’s Common Stock in a transaction structured as a block trade at a price of $70.55 per share. Depending on market conditions, their continuing evaluation of the business and prospects of the Issuer and other factors, Aggregator, Co-Invest II and other Reporting Persons may dispose of or acquire additional shares of the Issuer.

    Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:

    (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

    (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

    (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

    (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

    (e) Any material change in the present capitalization or dividend policy of the Issuer;

    (f) Any other material change in the Issuer’s business or corporate structure;

    (g) Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

    (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;


    CUSIP No. 03940C 10 0    Schedule 13D/A    Page 9

     

    (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or

    (j) Any action similar to any of those enumerated above.

     

    Item 5. 

    Interest in Securities of the Issuer.

    The response set forth in Item 5 of the Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:

    (a), (b) The information contained in rows 7, 8, 9, 10, 11, and 13 on each of the cover pages of this Amendment No. 5 is incorporated by reference in its entirety into this Item 5.

    (c) Except as described herein, no transactions in shares of Common Stock were effected during the past 60 days by the Reporting Persons.

    (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Shares beneficially owned by any of the Reporting Persons.

    (e) Each of the Reporting Persons has ceased to own beneficially five precent (5%) or more of the Issuer’s Common Stock.

     

    Item 7.

    Material to be Filed as Exhibits

     

    Exhibit 1     Joint Filing Agreement
    Exhibit 2    Power of Attorney (incorporated by reference to Exhibit 2 of Amendment No. 2)


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: March 25, 2024

     

    SR ONE CAPITAL FUND I AGGREGATOR, L.P.

    By: SR One Capital Partners I, LP

    By: SR One Capital Management, LLC

    By:   /s/ Sasha Keough
      Name:   Sasha Keough
      Title:   Attorney-in-Fact

    SR ONE CAPITAL PARTNERS I, LP

    By: SR One Capital Management, LLC, its General Partner

    By:   /s/ Sasha Keough
      Name:   Sasha Keough
      Title:   Attorney-in-Fact

    SR ONE CO-INVEST II, LP

    By: SR One Co-Invest II Manager, LLC its Manager

    By: SR One Capital Management, LLC, its Manager

    By:   /s/ Sasha Keough
      Name:   Sasha Keough
      Title:   Attorney-in-Fact

    SR ONE CO-INVEST II MANAGER, LLC

    By: SR One Capital Management, LLC, its Manager

    By:   /s/ Sasha Keough
      Name:   Sasha Keough
      Title:   Attorney-in-Fact
    SR ONE CAPITAL MANAGEMENT, LLC
    By:   /s/ Sasha Keough
      Name:   Sasha Keough
      Title:   Attorney-in-Fact

     

    *

    Simeon George


    */s/ Sasha Keough

    Sasha Keough
    As attorney-in-fact

    This Amendment No. 5 was executed by Sasha Keough on behalf of the entities and individual listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2 to Amendment No. 2.

     

    Get the next $ACLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACLX

    DatePrice TargetRatingAnalyst
    10/8/2024$109.00Buy
    Redburn Atlantic
    9/3/2024Overweight
    Cantor Fitzgerald
    5/31/2024$70.00Overweight
    Piper Sandler
    3/7/2024$81.00Overweight
    Morgan Stanley
    1/4/2024$65.00 → $71.00Buy
    Needham
    12/19/2023$66.00Sector Outperform
    Scotiabank
    10/30/2023Outperform
    TD Cowen
    10/17/2023$52.00Buy
    UBS
    More analyst ratings

    $ACLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Behbahani Ali

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:33:05 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Galligan Andrew H

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:24:21 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Patel Kavita

      4 - Arcellx, Inc. (0001786205) (Issuer)

      5/30/25 4:20:49 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    SEC Filings

    See more
    • SEC Form 8-K filed by Arcellx Inc.

      8-K - Arcellx, Inc. (0001786205) (Filer)

      5/28/25 4:34:31 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcellx Inc.

      SCHEDULE 13G/A - Arcellx, Inc. (0001786205) (Subject)

      5/15/25 4:30:15 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Arcellx Inc.

      8-K - Arcellx, Inc. (0001786205) (Filer)

      5/14/25 10:08:40 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Arcellx with a new price target

      Redburn Atlantic initiated coverage of Arcellx with a rating of Buy and set a new price target of $109.00

      10/8/24 7:12:00 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Arcellx

      Cantor Fitzgerald initiated coverage of Arcellx with a rating of Overweight

      9/3/24 7:38:42 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Arcellx with a new price target

      Piper Sandler initiated coverage of Arcellx with a rating of Overweight and set a new price target of $70.00

      5/31/24 7:34:12 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

      -- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market

      3/20/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

      REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters. 

      6/21/22 4:05:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Appoints Michelle Gilson as Chief Financial Officer

      FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.

      5/23/22 4:05:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

      Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowen's 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at 8:30 p.m. CEST (Virtual and In-Person, Milan, Italy) A live webcast of these discussions will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcasts will be archived and available for 3

      5/21/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

      -- Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR at a median follow-up of 12.6 months -- -- No delayed neurotoxicities including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel -- -- iMMagine-1 data to be presented during an oral presentation at EHA2025 on Saturday, June 14, 2025 -- -- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies f

      5/14/25 9:30:00 AM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

      -- iMMagine-1 data accepted for Oral Presentation at EHA -- -- iMMagine-3 study updated to include MRD negativity as a dual primary endpoint -- -- Added two new Board members with commercial and operational expertise -- -- Ended the quarter with $565M in cash, which is expected to fund operations into 2028 -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. "Delivering therapies that can positively impact patients' lives is our mission," said Rami Elg

      5/8/25 4:00:00 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ACLX
    Financials

    Live finance-specific insights

    See more
    • SEC Form SC 13G filed by Arcellx Inc.

      SC 13G - Arcellx, Inc. (0001786205) (Subject)

      11/22/24 4:12:28 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

      SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

      11/14/24 4:35:36 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

      SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

      11/14/24 4:31:50 PM ET
      $ACLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

      -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. --   -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma --  -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx

      12/9/22 8:15:00 AM ET
      $ACLX
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care